drugset / Trial / NCT00421226

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male Volunteers

NCT00421226

Phase 1 Completed 48 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of ACZ885 administered via intravenous infusion and subcutaneous injection in healthy Japanese male volunteers.

Timeline

Start
2006-12
Primary completion
2007-10
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Canakinumab Monoclonal antibody Intravenous

Indications

No indication recorded.